PRL and amyloidosis: The demonstration of the modulation of Tau phosphorylation during pregnancy and lactation [8] or the decrease in b-amyloid aggregation and Tau phosphorylation in the hippocampus, described in transgenic animal models of amyloidosis after administration of prolactin analogs [9], also supports the action of prolactin as a neuroprotector.